ClinicalTrials.gov
public full text
Public Domain
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Through an observational clinical study, partly prospective and partly retrospective, based on the collection of clinical data and on in vitro experimental analyses carried out on residual biological samples obtained during routine clinical procedures, it is proposed to identify predictive biomarkers of in vivo response to first-line therapies.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rapid dFLC Response Predict CHR in AL Amyloidosis#801898
- Single-Cell Analysis Reveals Inflammatory-Immunosuppressive Niches in Daratumumab-Resistant Primary AL Amyloidosis#143869
- Single-Cell Analysis Reveals Inflammatory–Immunosuppressive Niches in Daratumumab-Resistant Primary AL Amyloidosis#147919
- Daratumumab for the Treatment of Patients With AL Amyloidosis#1047466
- Exploring Biomarkers in Hereditary Transthyretin Amyloidosis#885121
Record · ID 810234
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive